Introduction
============

Glaucoma is an optic neuropathy, characterized by elevated intra-ocular pressure (IOP) which results in retinal ganglion cell (RGC) death and vision loss \[[@r1]\]. Primary congenital glaucoma (PCG; OMIM [231300](http://www.ncbi.nlm.nih.gov/omim/231300)) is a severe form of glaucoma which manifests in the neonatal/early infantile period with a classic triad of symptoms viz. epiphora (excessive tearing), photophobia (hypersensitivity to light), and blepharospasm \[[@r2]\]. The prevalence of congenital glaucoma varies across ethnic communities and geographical boundaries \[[@r3]\]. In the Indian state of Andhra Pradesh, its prevalence is estimated to be around 1:3,300 and accounts for 4.2% of all cases of childhood blindness \[[@r4]\].

Genetic heterogeneity is the hallmark of PCG and three chromosomal loci (I) 2p21 (GLC3A (GLC stands for glaucoma); OMIM [231300](http://www.ncbi.nlm.nih.gov/omim/231300)) \[[@r5]\], (II) 1p36 (GLC3B; OMIM [600975](http://www.ncbi.nlm.nih.gov/omim/600975)) \[[@r6]\], and (III) 14q24.3 (GLC3C) \[[@r7]\] have been mapped by linkage analysis, of which only the GLC3A locus harboring the human Cytochrome P450 gene (*CYP1B1*; OMIM [601771](http://www.ncbi.nlm.nih.gov/omim/601771)) has been characterized \[[@r8]\]. *CYP1B1* exhibits a high degree of allelic heterogeneity and more than 79 different mutations associated with PCG have been identified \[[@r9]\]. The proportion of PCG cases with *CYP1B1* mutations vary widely across different populations and are highest among the inbred Slovakian Gypsy \[[@r10]\] and Saudi Arabian populations \[[@r11]\] which exhibit allelic homogeneity.

Earlier we reported *CYP1B1* mutations as a predominant cause for PCG phenotype \[[@r12],[@r13]\]. We observed *CYP1B1* mutations in 42.66% PCG cases (32/75; 13 cases were homozygous, 8 were compound heterozygous, and 11 were heterozygous for *CYP1B1* mutations). However, 57.34% of these cases did not show the involvement of *CYP1B1*.

This led us to explore the role of other genes to understand their possible implications in the disease pathogenesis. The myocilin gene implicated in juvenile open angle glaucoma (JOAG) and in adult-onset primary open angle glaucoma (POAG) \[[@r14]\] was chosen as the potential candidate for screening these cases. The myocilin gene (*MYOC*) exhibits a wide spectrum of mutations and accounts for 2--5% cases of POAG \[[@r15]\] and in 5.5% of PCG \[[@r16]\]. *MYOC* is located on chromosome 1 at 1q25 and codes for myocilin/trabecular meshwork-induced glucocorticoid response (TIGR) protein. Most tissues of the eye express MYOC, including trabecular meshwork, sclera, ciliary body, and retina \[[@r17],[@r18]\]. An earlier report showed that MYOC interacts with CYP1B1 through a digenic mechanism in causing JOAG \[[@r19]\].

Forkhead box protein C1 (*FOXC1/FKHL7*), another gene, was also selected for mutation analysis in PCG cases which were either negative or heterozygous for *CYP1B1* mutations. A recent study from Southern India has reported involvement of *FOXC1* mutations in PCG \[[@r20]\]. *FOXC1* is a member of the winged helix/forkhead family of transcription factors. It is located on 6p25 and has single exon that codes for 553 amino acids long protein \[[@r21]\]. The FOXC1 protein is expressed in various ocular and non-ocular tissues \[[@r22],[@r23]\] and is found in periocular mesenchyme cells that give rise to ocular drainage structures such as the iris, cornea, and trabecular meshwork \[[@r24]\]. Both the *FOXC1* null (*FOXC1*^−/−^) and the heterozygous (*FOXC1*^+/−^) mice were found to have anterior segment abnormalities similar to those in humans with anterior segment dysgenesis (ASD) and congenital glaucoma \[[@r25]\]. In this study we have screened *MYOC* gene in 75 PCG cases and *FOXC1* gene in 54 PCG cases (negative/heterozygous for *CYP1B1* mutations) to understand the role of these two gene in the pathogenesis of this blinding disorder.

Methods
=======

Congenital glaucoma cases presenting at the Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences (AIIMS), New Delhi, India, were enrolled for this study. After ethical approval of the Institutional Review Board (IRB00006862; AIIMS) a total of 75 PCG cases were screened for *MYOC* sequence variations while *FOXC1* was screened in 54 cases (either negative or heterozygous for *CYP1B1* mutations; [Table 1](#t1){ref-type="table"}). The diagnosis involved clinical, ocular and systemic examination. Inclusion criteria of the patients were increased corneal diameter (\>12.0 mmHg) and raised IOP (\>21 mmHg) with presence/absence of Haab's striae and optic disc changes (where examination was possible). Symptoms of epiphora and photophobia were the additional inclusion factors. The age of onset ranged from birth to 3 years.

###### Clinical phenotype and *CYP1B1* mutation status of PCG cases.

  **Pt. ID**   **Age of onset of disease**   **Sex**   **Age at presentation/Sampling**   **Corneal Diameter (mm) OS/OD**   **Buphthalmos**       **IOP OS**   **IOP OD**   **Haabs' striae**   **Last Cup Disc ratio OS/OD**   **Corneal edema**   **Mutations**               **Treatments**
  ------------ ----------------------------- --------- ---------------------------------- --------------------------------- --------------------- ------------ ------------ ------------------- ------------------------------- ------------------- --------------------------- ----------------------------------------------------------
  PCG01        By birth                      M         12 years                           15x15/15x15.5                     OU                    40           30           OU                  Total cupping                   OU                  R390H (H)                   Medical and OU 3XTrab/Trab+MMC
  PCG02        By birth                      F         10 years                           13x13/13x13                       OU                    36           40           OU                  0.5:1/0.6:1                     OU                  R390H (H)                   Medical and OU 1XTrab/Trab+MMC
  PCG03        By birth                      F         7 months                           15x14/15x15                       OU; OD\>OS            26           38           Absent              Hazy MEDIA                      Absent              R390H (H)                   Medical and OU 1XTrab/Trab+MMC; OS 1XTrab/Trab+MMC
  PCG04        By birth                      M         10 months                          12x11/12x12                       Absent                22           24           Absent              0.4:1/0.4:1                     Absent              ---                         Medical and OU Trab/Trab+MMC
  PCG05        4 months                      M         5 months                           14.5x15/15x15                     OU; OD\>OS            28           28           OU                  0.7:1/0.7:1                     OU                  R368H (H)                   Medical and OU 2XTrab/Trab+MMC
  PCG06        By birth                      M         4 months                           12x13/12x13                       OU                    22           23           OU                  0.5:1/0.5:1                     OU                  ---                         Medical and OU Trab/Trab+MMC
  PCG07        By birth                      F         18 months                          12x13/11x11.5                     OS                    38           14           Absent              0.4:1/0.4:1                     Absent              ---                         Medical and OU Trab/Trab+MMC
  PCG08        1 month                       F                                            NA                                OD                    23           25           Absent              Hazy media                      One eye             ---                         Medical and OD Trab/Trab+MMC
  PCG09        2 months                                13 months                          12x12/12x12                       Absent                22           22           Absent              NA                              Absent              ---                         Medical and OU Trab/Trab+MMC
  PCG010       1 month                       F         1 month                            NA                                OD                    23           24           Absent              NA                              One eye             ---                         Medical and OD Trab/Trab+MMC
  PCG011       1 year                        M         4 months                           14x14/14x15                       OU; OD\>OS            26           22           Absent              NA                              Absent              E229K (h)                   Medical and OU 1XTrab/Trab+MMC
  PCG012       By birth                      M         58 months                          14x14.5/14x14.4                   OU                    32           32           Absent              NA                              Absent              R368H (h)                   Medical and OU 1XTrab/Trab+MMC
  PCG013       By birth                      F         2 months                           14x14/14x14                       OU                    31           30           Absent              Hazy media                      Absent              R390H (H)                   Medical and OU 2XTrab/Trab+MMC
  PCG014       By birth                      F         1 month                            NA                                OU                    25           24           Absent              Hazy media                      Absent              E229K (h)                   Medical and OU 2XTrab/Trab+MMC
  PCG015       By birth                      M         3 months                           14.5x14/13.5x13                   OU; OS\>ODR           32           32           Absent              0.6:1/0.6:1                     Absent              M132R (H)                   Medical and OU 2XTrab/Trab+MMC
  PCG016       By birth                      M         6 months                           11x11/12x12.5                     OD                    18           26           Absent              0.4:1/0.5:1                     Absent              ---                         Medical and OD Trab/Trab+MMC
  PCG017       By birth                      M         9 months                           14x14/14x14.5                     OU                    30           28           Absent              NA                              Absent              Ter\@223 (H)                Medical and OU 2XTrab/Trab+MMC
  PCG018       By birth                      M         3.4 years                          14.5x14/14x14                     OU; OS\>OD            20           20           Absent              NA                              Absent              ---                         Medical and OU Trab/Trab+MMC
  PCG019       By birth                      F         7 months                           12x12.5/12x12                     OU                    22           22           Absent              0.5:1 1                         Absent              Ter\@223 (h)                Medical and OU 2XTrab/Trab+MMC
  PCG020       By birth                      M         7 years                            12x13/13x13                       OU; OD\>OS            18           37           Absent              Hazy media                      Absent              ---                         Medical and OU1X Trab/Trab+MMC
  PCG021       By birth                      M         2 years                            15x16/11.5x12                     OS                    32           15           OU                  Hazy media                      Absent              Ter\@223 (h)                Medical and 2X Trab/Trab+MMC OS
  PCG022       By birth                      F         10 months                          15x15/16x16                       OU; OD\>OS            28           28           OU                  0.7:1/0.5:1                     Absent              p.L24R (H)                  Medical and OS 2XTrab/Trab+MMC
  PCG023       By birth                      F         4 months                           14x15/14x15                       OU                    34           36           OU                  Hazy media                      OU                  ---                         Medical and OU 1X Trab/Trab+MMC
  PCG024       By birth                      M         1 months                           14x13/14x13                       OU                    30           24           Absent              0.7:1/0.7:1                     OU                  ---                         Medical and OU 1X Trab/Trab+MMC
  PCG025       By birth                      F         18 years                           NA                                Absent                32           10           Absent              NA                              Absent              ---                         Medical and OS Trab/Trab+MMC
  PCG026       By birth                      M         2 years                            14x15/14x15                       OU                    22           22           Absent              Hazy media                      OU                  ---                         Medical and OU Trab/Trab+MMC
  PCG027       By birth                      F         2 years                            13x13.5/15x14.5                   OU;                   22           22           Absent              0.8:1/0.8:1                     Absent              ---                         Medical and OU 1X Trab/Trab+MMC
  PCG028       By birth                      M         2.5 years                          13x13.5/13x13.5                   OU                    20           20           Absent              hazy media                      One eye             ---                         Medical and OU 1X Trab/Trab+MMC
  PCG029       By birth                      F         3 months                           15x15/14x14                       OU                    28           27           OU                  Hazy media                      OU                  Ter\@223 (h)                Medical and 2X Trab/Trab+MMC
  PCG030       By birth                      M         1 month                            13x13.5/13.5x13                   OU                    26           26           Absent              0.7:1/0.7:1                     One eye             ---                         Medical and 1X OU Trab/Trab+MMC
  PCG031       By birth                      M         4 months                           11x14/14x15                       OU                    34           36           Absent              Hazy media                      Absent              ---                         Medical and 1X OU Trab/Trab+MMC
  PCG032       By birth                      M         10 months                          15x15/12x12                       OS                    18           14           Absent              0.3:1/0.3:1                     Absent              ---                         Medical and 1X OS Trab/Trab+MMC
  PCG033       By birth                      M         1 year                             13x13/11x11                       OS                    12           12           Absent              0.2:1/NO glow                   One eye             ---                         Medical and 1X OS Trab/Trab+MMC
  PCG034       By birth                      M         2 months                           14x14/14x14                       OU                    22           24           Absent              NA                              Absent              R390H (h); Ter\@223 (h      Medical and 1X OU Trab/Trab+MMC
  PCG035       By birth                      M         3 months                           13x13/13x12                       OS                    18           16           Absent              no glow                         Absent              ---                         Medical and 1X OS Trab/Trab+MMC
  PCG036       By birth                      M         1 month                            15x15/15x15.5                     OU                    25           26           Absent              0.8:1 1                         Absent              R390H (H); E229K (h)        Medical and 1X OD Trab/Trab+MMC
  PCG037       By birth                      M         1 month                            14x14/11x11                       OU;OS\>OD             18           22           Absent              Hazy media                      One eye             ---                         Medical and 1X OU Trab/Trab+MMC
  PCG038       By birth                      M         3.5 years                          corneal: Dulcer/14x14             OD                    18           20           Absent              hazy media                      OU                  ---                         Medical and 1X OD Trab/Trab+MMC
  PCG039       By birth                      M         4.5 years                          13x13/12x13.5                     OU                    36           34           Absent              NT cupping                      OU                  R368H (h); Ter\@223 (h)     Medical and 1X OUTrab/Trab+MMC
  PCG040       By birth                      F         2 months                           11.5x12.5/12x13                   OU; OD\>OS            23           23           Absent              Hazy media                      OU                  Ter\@223 (h)                Medical and OD 1XTrab/Trab+MMC
  PCG041       By birth                      M         11 months                          12x10/12x12.5                     OU; OD\>OS            40           26           Absent              Hazy media                      OU                  R390H (H): Ter\@223 (h)     Medical and OU 1XTrab/Trab+MMC; 1XTrab+Trab+mmc OD, 1XPK
  PCG042       By birth                      M         5 days                             13x13/13x13                       OU                    22           24           Absent              Hazy media                      OU                  R368H (H) F190L (H)         Medical and 1XTrab/Trab+MMC OU
  PCG043       By birth                      F         I2 months                          12x12/12x12                       OU                    22           26           OU                  0.8:1 1                         Absent              R390H (h) G329D (h)         Medical and 1X OU Trab/Trab+MMC
  PCG044       By birth                      M         4 years                            14x14/14x14                       OU                    26           24           Absent              0.8:1/0.9:1                     Absent              Ter\@223(h)                 Medical and 1X OU Trab/Trab+MMC
  PCG045       By birth                      M         1 month                            12x12/12x12.5                     OU                    20           22           Absent              0.5:1/0.5:1                     Absent              E229K (h), R390H (h)        Medical and 1X OU Trab/Trab+MMC
  PCG046       By birth                      M         6 months                           13x13/13x13.5                     OU                    24           16           Absent              0.5:1/0.3:1                     OU                  ---                         Medical and1X OU Trab/Trab+MMC
  PCG047       By birth                      F         5 months                           14.5x14/14x14                     OU                    30           20           Absent              0.7:1/0.9:1                     One eye             ---                         Medical and 1X OU Trab/Trab+MMC
  PCG048       By birth                      M         11 months                          13x13.5/12x13                     OU                    28           26           Absent              NA                              Absent              ---                         Medical and 1X OU Trab/Trab+MMC
  PCG049       By birth                      M         6 months                           18x20/14x16                       OU                    24           22           Absent              OS no glow/0.5:1                Absent              ---                         Medical and 1X OU Trab/Trab+MMC
  PCG050       By birth                      F                                            11x11.5/11x11.5                   OU                    26           30           Absent              0.3:1/0.3:1                     Absent              ---                         Medical and 1X OU Trab/Trab+MMC
  PCG051       By birth                      F         36 months                          11x11.5/13x13                     OU;OD\>OS             22           28           Absent              0.8:1/0.9:1                     OU                  ---                         Medical and 1X OU Trab/Trab+MMC; OU cataract surgery
  PCG052       By Birth                      F         2 months                           12.5x13/12.5x13                   OU                    20           20           Absent              Hazy media/0.5:1                Absent              ---                         Medical and 1X OU Trab/Trab+MMC
  PCG053       By birth                      F         4 months                           11.5x12/12x12                     OU; OD\>OS            40           23           Absent              Hazy media                      OU                  ---                         Medical and 1X OU Trab/Trab+MMC
  PCG054       By birth                      M         9 months                           15x14.5/15x14.5                   OU                    26           26           Absent              Absent glow                     Absent              ---                         Medical and 1X OU Trab/Trab+MMC
  PCG055       By birth                      M         8 months                           Phthisic eye/12x12                OD; OS Phthisic eye   na           37           Absent              NA/0.9:1                        OU                  p.I94X (H)                  Medical and 1X OD Trab/Trab+MMC
  PCG056       By birth                      F         12 months                          14.5x14.5/14x14                   OU; OS\>OD            30           28           OU +ve              Hazy media                      OU                  p.Q340H (H) + p.R390H (H)   Medical and 1X OU Trab/Trab+MMC
  PCG057       By birth                      M         3 months                           13x13/13.5x13.5                   OU; OD\>OS            28           30           Absent              0.7:1/0.7:1                     Absent              ---                         Medical and 1X OU Trab/Trab+MMC
  PCG058       By birth                      M         15 months                          14x14/12.5x12.5                   OU; OS\>OD            20           16           Absent              total cupping/ 0.5:1            Absent              ---                         Medical and 1X OU Trab/Trab+MMC
  PCG059       By birth                      F         10 months                          14x14.5/13.5x14                   OU; OS\>OD            31           31           OS                  NA                              Absent              ---                         Medical and 1X OU Trab/Trab+MMC
  PCG060       7 months                      F         41 months                          14x14/13x13.5                     OU; OS\>OD            24           18           Absent              0.4:1/0.6:1                     Absent              ---                         Medical and 1X OU Trab/Trab+MMC
  PCG061       By birth                      M         4 months                           15.5x15/14x14                     OU; OS\>OD            30           34           OU                  Not visible/0.9:1               OU                  p.H279D (h)                 Medical and 1X OU Trab/Trab+MMC
  PCG062       By birth                      M         8 months                           11x11.5/10x11.5                   OU; OS\>OD            22           16           Absent              0.6:1/0.6:1                     Absent              ---                         Medical and 1X OU Trab/Trab+MMC
  PCG063       3 months                      M         12 months                          12x12/11x12.5                     OU; OS\>OD            22           23           Absent              0.4:1/0.4:1                     Absent              ---                         Medical and 1X OU Trab/Trab+MMC
  PCG064       By birth                      M         1 month                            12x12/11.5x11.5                   OU; OS\>OD            28           24           Absent              not visible/0.7:1               Absent              p.R390C (h)                 Medical and 1X OU Trab/Trab+MMC
  PCG065       By birth                      M         6 months                           13x13/12.5x13                     OU; OS\>OD            25           26           Absent              0.7:1/0.7:1                     OU                  p.E229K (h)                 Medical and 1X OU Trab/Trab+MMC
  PCG066       3 months                      M         13 months                          12.5x12/12.5x12                   OU                    22           24           Absent              0.4:1/0.4:1                     Absent              ---                         Medical and 1X OU Trab/Trab+MMC
  PCG067       11 months                     M         132 months                         12x13/13x14                       OU; OD\>OS            21           24           Absent              not visible                     OU                  ---                         Medical and 1X OU Trab/Trab+MMC
  PCG068       By birth                      M         6 months                           13x13/13.5x14                     OU; OD\>OS            26           28           Absent              0.8:1/0.8:1                     OU                  p.R368H (H)                 Medical and 1X OU Trab/Trab+MMC
  PCG069       By birth                      M         4 months                           13x13/12x13                       OU; OS\>OD            24           26           Absent              0.5:1/0.6:1                     Absent              ---                         Medical and 1X OU Trab/Trab+MMC
  PCG070       By birth                      M         45 days                            15x15/15x14.5                     OU/; OS\>OD           30           40           Not visible         not visible                     OU                  p.R355X (H)                 Medical and 1X OU Trab/Trab+MMC
  PCG071       13 months                     M         18 months                          12x12/12x12                       OU                    22           23           Absent              0.4:1/0.4:1                     Absent              ---                         Medical and 1X OU Trab/Trab+MMC
  PCG072       By birth                      M         45 days                            12x12/12x11.5                     OU; OS\>OD            20           24           Absent              no glow                         OU                  ---                         Medical and 1X OU Trab/Trab+MMC
  PCG073       By birth                      M         2 months                           12.5x13/11x12                     OU; OS\>OD            22           22           Absent              Hazy media                      OU                  ---                         Medical and 1X OU Trab/Trab+MMC
  PCG074       By birth                      M         8 months                           14x14.5/15x15                     OU;OS\>OD             28           24           OU                  No glow                         OU                  p.R368 (H)                  Medical and 1X OU Trab/Trab+MMC
  PCG075       By birth                      M         1 year                             13x13.5/14x14                     0U; OD\>OS            20           20           Absent              No glow                         OU                  R390H (H)                   Medical and 1X OU Trab/Trab+MMC

Key: M- male; F- female; H- homozygous; h-heterozygous; X- times; Trab/Trab+MMC- combined trabeculotomy trabeculectomy and mitomycin C treatment; OD- right eye; OS- left eye; OU- both eyes; NA- not available.

All patients with history of blood transfusion, TORCH (Toxoplasmosis; Rubella; Cytomegalovirus; Herpes Simplex Virus) infection and drug intake by mother during pregnancy were excluded. Glaucoma cases other than PCG were excluded. Detailed family history of ocular or other hereditary disorders up to three generations were taken, and pedigree charts were constructed.

Control group
-------------

Seventy five ethnically matched normal individuals without any ocular/systemic disorders were enrolled as controls for *MYOC* and 50 for *FOXC1* analysis. Peripheral blood samples were collected from patients and controls by venipuncture in ethylenediaminetetra-acetic acid (EDTA) vacutainers only after informed consent and stored in −80 °C until further use.

Mutation screening and sequence analysis
----------------------------------------

DNA was isolated from the peripheral blood using the Phenol chloroform method. All three exons with exon-intron boundaries were amplified from DNA using polymerase chain reaction (PCR) primers designed for *MYOC* (GenBank [AB006688](http://www.ncbi.nlm.nih.gov/nuccore/AB006688); available at [Genbank](http://www.ncbi.nlm.nih.gov/Genbank)) \[[@r26]\]. *FOXC1* primers ([Table 2](#t2){ref-type="table"}) were designed using National Center for Biotechnology Information (NCBI) [PRIMER3](http://www.ncbi.nlm.nih.gov/tools/primer-blast/) program. PCR amplifications for *FOXC1* primers were performed in a 40 μl volume containing 1.0 μl of 20 μM stock solution for each primer, 100 ng of genomic DNA, 1 unit of Taq polymerase (Banglore Genei P Ltd, Bengaluru, Karnataka, India), 0.1 mM of each dNTP and 4 μl of 10× PCR buffer (with 15 mM MgCl~2~), by means of 35 cycles of amplification, each consisting of 30 s denaturation at 94 °C, 50 s annealing at 56 °C −59 °C and 1 min extension at 72 °C and final extension at 72 °C for 5 min.

###### *FOXC1* primers used in this study.

  **Serial number**   **Primer sequence**        **Product size**
  ------------------- -------------------------- ------------------
  1                   1F- CCCGGACTCGGACTCGGC     649 bp
  ** **               1R- TCTCCTCCTTGTCCTTCACC   ** **
  2                   2F- GAGAACGGCAGCTTCCTG     708 bp
  ** **               2R-TTGCAGGTTGCAGTGGTAGGT   ** **
  3                   3F-GGCCAGAGCTCCCTCTACA     636 bp
  ** **               3R-CTGCTTTGGGGTTCGATTTA    ** **

All PCR products were analyzed on 1.8% agarose gel, stained with ethidium-bromide (EtBr 10 mg/ml). Agarose gel was analyzed using gel documentation system (Applied biosystems, Carlsbad, CA). Amplified PCR products were purified using gel/PCR DNA fragments extraction kit (Catalog number DF100; Geneaid Biotech Ltd., Sijhih City, Taiwan). Purified PCR product were sent for sequencing at [MCLAB](http://www.mclab.com/product.php?productid=19071) (Molecular Cloning Laboratories, South San Francisco, CA). DNA sequences were analyzed against the *MYOC* [reference](http://may2009.archive.ensembl.org/Homo_sapiens/Gene/Sequence?g=ENSG00000034971) sequence and the *FOXC1* [reference](http://may2009.archive.ensembl.org/Homo_sapiens/Gene/Sequence?g=ENSG00000054598) sequence using [ClustalW2](http://www.ebi.ac.uk/Tools/clustalw2/index.html) provided by the European Molecular Biology Laboratory (EMBL) European Bioinformatics Institute (EBI).

Computational assessment of missense mutations
----------------------------------------------

Two homology based programs [PolyPhen](http://genetics.bwh.harvard.edu/pph/) (Polymorphism Phenotyping) and [SIFT](http://sift.jcvi.org/) (Sorting Intolerant From Tolerant) analysis tool were used to predict the functional impact of missense changes identified in this study \[[@r27],[@r28]\]. The prediction is based on the position-specific independent counts (PSIC) score derived from multiple sequence alignments of observations. [PolyPhen](http://genetics.bwh.harvard.edu/pph/) scores of \>2.0 indicate the polymorphism is probably damaging to protein function. Scores of 1.5--2.0 are possibly damaging, and scores of \<1.5 are likely benign. [SIFT](http://sift.jcvi.org/) is a sequence homology-based tool that sorts intolerant from tolerant amino acid substitutions and predicts whether an amino acid substitution in a protein will have a phenotypic effect \[[@r29],[@r30]\]. Positions with normalized probabilities less than 0.05 are predicted to be deleterious and, those greater than or equal to 0.05 are predicted to be tolerated. We have also used an improved [splice](http://www.fruitfly.org/seq_tools/splice.html) site predictor tool \[[@r31]\] to predict whether a nucleotide change is likely to create a splice site.

Statistical analysis
--------------------

The frequency of nucleotide variation between cases and controls was calculated by χ^2^/Fisher's exact test and a p-value ≤0.05 was considered significant.

Results
=======

A total of five nucleotide changes (2 in promoter region, 2 in coding region and 1 in intronic region) were observed in *MYOC* and two sequence variations (GGC375ins and GGC447ins) were observed in *FOXC1* in this study. Details of all these changes are given below.

Myocilin (*MYOC*) gene
----------------------

### −126 Thymine to Cytosine (−126T\>C)

This nucleotide change resulted in thymine (T) being replaced by cytosine(C; [Figure 1](#f1){ref-type="fig"}) at position g.169888563 or 126 base pairs upstream (−126 position). This change was homozygous in one (PCG043) and heterozygous in one case (PCG053) but was absent in controls.

![DNA sequence chromatogram of *MYOC* equivalent to bases −121 to −132. **A**: The reference sequence derived from control is shown. **B**: Sequence derived from congenital glaucoma patient PCG043 shows heterozygous −126T\>C nucleotide change.](mv-v16-1996-f1){#f1}

### −83 Guanine to Adenine (−83G\>A)

This nucleotide change resulted in guanine (G) being replaced by alanine (A; [Figure 2](#f2){ref-type="fig"}) at position g.169888457 or 83 base pairs upstream (−83 position). This change was homozygous in five cases (PCG07, 015, 034, 040, and 062) and heterozygous (PCG06, 15, 34, and 40) in four cases. This change was also present in 2 controls.

![DNA sequence chromatogram of *MYOC* equivalent to bases −76 to −88. **A**: The reference sequence derived from control is shown. **B**: Sequence derived from congenital glaucoma patient PCG015 shows homozygous −83G\>A nucleotide change.](mv-v16-1996-f2){#f2}

### Arginine76Lysine (p.R76K)

This nucleotide change resulted in G being replaced by A ([Figure 3](#f3){ref-type="fig"}) at position g.169888148; coding nucleotide number c.127. This resulted in a codon change from AGA to AAA and amino acid change from arginine to lysine (p.R76K) a non-synonymous mutation in *MYOC*. This change was homozygous in five patients (PCG007, 015, 034, 040, and 052) and heterozygous in twenty five patients (PCG005, 006, 011, 012, 0016--019, 021, 022, 027, 033, 036, 043, 044, 046, 049, 059, 062, and 065--069) and was also present in 12 controls.

![DNA sequence chromatogram of *MYOC* exon 1 equivalent to codon 75--78. **A**: The reference sequence derived from control is shown. **B**: Sequence derived from congenital glaucoma patient PCG005 shows homozygous c.127G\>A, which predicts a codon change AGA\>AAA and p.R76K change.](mv-v16-1996-f3){#f3}

### IVS2+35 Guanine to Adenine (IVS2+35G\>A)

This nucleotide change resulted in G being replaced by A ([Figure 4](#f4){ref-type="fig"}) at position g.169874325 or 35 base pairs downstream (IVS2+35 position) ; This change was homozygous in forty seven patients (PCG002, 004, 006--009, 011--013, 015, 017, 019--022, 026--029, 033--036, 039--041, 043--046, 049--060, 063--066, and 069) and heterozygous in thirteen patients (PCG001, 003, 005, 010, 016, 018, 023, 037, 042, 054, 061, 062, and 067) and was also present in 25 controls.

![DNA sequence chromatogram of *MYOC* equivalent to IVS2+31 to IVS2+42 **A**: The reference sequence derived from control is shown. **B**: Sequence derived from congenital glaucoma patient PCG004 shows homozygous IVS2+35G\>A nucleotide change.](mv-v16-1996-f4){#f4}

### Tyrosine347Tyrosine (p.Y347Y)

This mutation resulted in T being replaced by C ([Figure 5](#f5){ref-type="fig"}) at position g.169872162; coding nucleotide number c.1041. This resulted in a codon change from TAT to TAC with no amino acid change (synonymous mutation) at 347 (p.Y347Y) in *MYOC* protein. Five cases (PCG029, 036, 043, 053, and 056) were heterozygous for this change while the same was absent in controls. All *MYOC* sequencing results have been tabulated ([Table 3](#t3){ref-type="table"}).

![DNA sequence chromatogram of *MYOC* exon 3 equivalent to codon 346--348. **A**: The reference sequence derived from control is shown. **B**: Sequence derived from congenital glaucoma patient PCG029 shows heterozygous c.1041T\>C, which predicts a codon change TAT\>TAC and p.Y347Y change.](mv-v16-1996-f5){#f5}

###### *MYOC* gene variations identified in this study with p-value at 95% confidence interval by using Pearson χ^2^/Fisher's exact test.

  ** **               ** **          ** **                 ** **              ** **          **Patient ID**   ** **                               
  ------------------- -------------- --------------------- ------------------ -------------- ---------------- --------------------- ------------- ----------------------------
  **Serial number**   **Location**   **Sequence change**   **Codon change**   **Mutation**   **PCG (n=75)**   **Controls (n=75)**   **p-value**   **Odds Ratio (at 95% CI)**
  1                   Promoter       −126T\>C              \-                 \-             2                0                     0.496         \-
  2                   Promoter       −83G\>A               \-                 \-             9                2                     0.055         4.97 (1.03--23.87)
  3                   Exon 1         c.227 G\>A            AGA\>AAA           p.R76K         30               12                    0.001         3.50 (1.61--7.56)
  4                   Intron 2       IVS2+35 G\>A          \-                 \-             60               25                    \<0.001       8.00 (3.80--16.80)
  5                   Exon 3         c.1041T\>C            TAT\>TAC           p.Y347Y        5                0                     0.058         \-

Forkhead box protein C1 (*FOXC1*) gene
--------------------------------------

### Insertion of GCG at g.1556820

Insertion of tri-nucleotide GCG at g.1556820 was observed in nine PCG cases (PCG006--008, 011, 023, 048, 051, 054, and 072) and four controls. This insertion was found in both alleles. This caused an insertion of an extra GGC triplet and an extra amino acid glycine at position 375 (GGC375ins). This leads to presence of seven glycine residues (generally six glycine are found) at amino acid position 375--381 instead of six glycine residues.

### Insertion of CGG at g.1557040

Homozygous insertion of tri-nucleotide CGG at g.1557040 was observed in six PCG cases (PCG006, 007, 051, 059, 063, and 065) and five controls. This caused an insertion of an extra GGC triplet which inserts an extra amino acid glycine at amino acid position 447 (GGC447ins). This leads to presence of eleven glycine residues at amino acid position 447--457.

Three PCG cases (PCG006, 007, and 051) had both insertions (GGC375ins and GGC447ins). No other changes were identified in any PCG patient. All *FOXC1* variations have been tabulated ([Table 4](#t4){ref-type="table"}).

###### *FOXC1* variations identified in this study with p-value at 95% confidence interval by using Pearson χ^2^/Fisher's exact test.

  ** **               ** **                 ** **          **Patient ID**   ** **                               
  ------------------- --------------------- -------------- ---------------- --------------------- ------------- ----------------------------
  **Serial number**   **Sequence change**   **Mutation**   **PCG (n=54)**   **Controls (n=50)**   **p-value**   **Odds ratio (at 95% CI)**
  1                   Ins GCC               GGC375ins      5                4                     0.240         2.3 (0.66--8.00)
  2                   Ins CGG               GGC447ins      6                5                     1             1.12 (0.32--3.94)

SIFT and PolyPhen analysis
--------------------------

There was only one missense change in *MYOC* in our study. The PSIC score of the p.R76K mutation was \<2 indicating that this change was benign to protein function. The SIFT score of p.R76K was 0.00 and was predicted to be deleterious for the protein function. Ideally, to call a change pathogenic both SIFT and PolyPhen results should be pathogenic. Since this change was present both in PCG and controls, it could be hypothesized that this change is non-pathogenic. Improved splice site prediction for IVS2+35G\>A showed that this location (IVS2+35) is not present at splice site and may not create a splicing error in *MYOC*.

Discussion
==========

PCG shows marked genetic heterogenity thus we have  screened *MYOC* in 75 PCG cases to study digenic inheritance and *FOXC1* in 54 cases which were either negative or heterozygous for the *CYP1B1* mutation for their involvement. To the best of our knowledge this is the first study from north India which involves *MYOC* and *FOXC1* screening in PCG. In our study three single nucleotide polymorphisms (SNPs; [Table 3](#t3){ref-type="table"}) were observed both in PCG cases as well as in controls while two were limited to cases only. The frequency of p.R76K, IVS2+35G\>A, and p.Y347Y in *MYOC* was found to be statistically significant (p\<0.05) in our study. However, no pathogenic *MYOC* mutation was detected. A recent study showed that a small proportion of PCG cases that do not harbor *CYP1B1* mutations exhibit a heterozygous mutation in the *MYOC* gene \[[@r16]\]. Digenic inheritance of the mutant *MYOC* and *CYP1B1* alleles has also been demonstrated in juvenile-onset POAG and *CYP1B1* has been suggested to be a modifier of *MYOC* expression \[[@r19]\]. The heterozygous p.Gln48His *MYOC* mutation was first reported in two sporadic cases of JOAG and an adult-onset POAG case from eastern India. Later this change was also reported in a JOAG family and in a sporadic POAG case from India \[[@r32]\].

Although IVS2+35G\>A was not at splice location but recent studies have revealed that intronic sequences may be associated with gene regulation. Intronic mutation, therefore, may be involved in the disease irrespective of whether the mutated base was at splice site \[[@r33]\]. Two promoter sequence variations (−126T\>C and −83G\>A) were observed in this study. These variations do not alter any known promoter or enhancer binding sites and are found in similar frequency in  patients and controls \[[@r34]\]. There is no evidence from literature that the −83G\>A and −126T\>C variations are associated with either the steroid response or POAG \[[@r34]\]. Further, the majority (96%) of the steroid responders examined by Fingert et al. \[[@r34]\] harbored no variations that met the criteria for potential involvement in the steroid response phenotype, clearly indicating that variations in the proximal promoter are not a common cause of glaucoma. All these five changes of MYOC identified in this study are listed as a [neutral polymorphisms](http://www.myocilin.com/variants.php) and no pathogenic variation in *MYOC* was observed in this study.

Two changes (GGC375ins and GGC447ins) in *FOXC1* were observed in cases as well as in controls. The frequency of these *FOXC1* variations were found to be statistically non-significant (p\>0.05) in our study. Both of these changes have already been described in the literature as neutral polymorphisms \[[@r20],[@r35],[@r36]\]. The presence of mutations in the *FOXC1* gene in patients with PCG was initially described in an independent study conducted by Chakrabarti et al. \[[@r20]\] in 2009 from south India. In addition, *FOXC1* mutations have been implicated in anterior segment dysgenesis (ASD) such as iridogoniodysgenesis, Axenfeld-Rieger syndrome (ARS) and Peter's anomaly that progress to glaucoma in 50% to 75% of cases \[[@r37]-[@r40]\]. Some of these ASD cases are associated with congenital or early-onset glaucomas, whereas some have glaucoma secondary to anterior segment anomalies \[[@r39]-[@r41]\]. Pathogenic *FOXC1* mutations were identified in PCG cases from southern India \[[@r20]\]. These findings indicate a potential role of the transcription factor *FOXC1* in the development of ocular tissues including the drainage structures. Since neither *CYP1B1* nor *MYOC* could explain the overall genetic contribution to PCG in earlier studies, we have also analyzed *FOXC1*. However, no pathogenic mutations were identified in *MYOC* and *FOXC1* gene in our patients. It, therefore, gives us a premise to assume the non-involvement of both *MYOC* and *FOXC1*.

This difference in mutation spectrum of north Indian and south Indian population may be explained on the basis of different evolutionary history/ethnicity of both populations. India has a heterogeneous population with people from north and south India being ethnically different. The ethno-linguistic composition of the population of India, Pakistan, Bangladesh, Nepal, Bhutan, Maldives, and Sri Lanka mostly falls within two large groups; Dravidian and Indo-Aryan. These groups are further subdivided into numerous subgroups, castes, and tribes. Indo-Aryans form the predominant ethno-linguistic group in Pakistan, India (the central, eastern, western, and northern regions), Nepal, Sri Lanka, and the Maldives. Dravidians form the predominant ethno-linguistic group in southern India and the northern and eastern regions of Sri Lanka (The Indian Genome Variation database \[IGVDb\]) \[[@r42]\]. The north Indian population is predominantly Aryan population while the south Indian population is Dravidian with totally different morphological phenotype and genetic background. Recently it has been shown that 'Ancestral North Indians' (ANI), are genetically close to Middle Easterners, Central Asians, and Europeans, whereas the other, the 'Ancestral South Indians' (ASI), is distinct from ANI and East Asians as they are from each other \[[@r43]\]. Thus, though mutations have been identified in *MYOC* and *FOXC1* in PCG cases from south India \[[@r16],[@r20]\], these two genes are not involved in PCG in our patients.

Conclusion
----------

This is the first study from north India showing non-involvement of *MYOC* and *FOXC1* in the pathogenesis of primary congenital glaucoma. Thus, it is important to screen other loci for involvement in congenital glaucoma in cases which are either negative or heterozygous for *CYP1B1* mutations to have a better insight in disease pathogenesis.
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